Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 4/20 | 0.48 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | MVD | P53602 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708227 | 1.00 | CNR1 (0.52) | CNR1CNR2ACEPREPMVD | |
| SCHEMBL3184833 | 0.89 | ACE (0.54) | ACEPREPMVDRENLMNA | |
| SCHEMBL3184400 | 0.89 | ACE (0.54) | ACEPREPMVDRENLMNA | |
| SCHEMBL3184389 | 0.89 | ACE (0.54) | ACEPREPMVDRENLMNA | |
| SCHEMBL3177953 | 0.85 | ACE (0.58) | ACEMVDRENLMNACYP2C19 | |
| SCHEMBL3168144 | 0.85 | ACE (0.58) | ACEMVDRENLMNACYP2C19 | |
| SCHEMBL3168154 | 0.85 | ACE (0.58) | ACEMVDRENLMNACYP2C19 | |
| SCHEMBL16254979 | 0.80 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL3718336 | 0.79 | HSD17B10 (0.49) | ACEMVDLMNACYP2C19HSD17B10 | |
| SCHEMBL3718332 | 0.79 | HSD17B10 (0.49) | ACEMVDLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885ACE 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.